Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHENIX trial of ctDNA-guided anti-HER2 discontinuation in HER2-positive metastatic breast cancer
2026-526268-18-00Phase 2Authorised
- Sponsor
- Foundation for the Incentive of Research
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab and pertuzumab in breast cancer and HER2-positive breast cancer, sponsored by Foundation for the Incentive of Research. Planned start Oct 2026; status: authorised.
02
Drugs
trastuzumabpertuzumab
03
Conditions
breast cancerHER2-positive breast cancer
Beyond the preview
Go deeper on 2026-526268-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526268-18-00.